Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants

Inclusion Criteria: * Males and females aged 18 years and older. * Clinical diagnosis of hepatitis C with GT1b. * Chronic hepatitis C treatment-naive participants. * Interleukin 28B genotype CC. * HCV ribonucleic acid \> 10,000 international units/milliliter at screening. * Female participants must be willing to use 2 effective methods of contraception during the dosing period and for 6 months after the last dose of ribavirin. * Male participants must be willing to use an effective barrier method of contraception throughout the dosing period and for 6 months after the last dose of ribavirin. Male participants must agree not to donate sperm while enrolled in the study and for 6 months after the last dose of ribavirin. * Willing to participate in all study activities and all study requirements. Exclusion Criteria: * Body mass index \> 36 kilograms/meter squared. * Pregnant or nursing females. * Clinically significant laboratory abnormalities at screening. * Previous participation in a clinical trial with protease inhibitor and/or non-structural protein 5A inhibitor. * Human immunodeficiency virus infection or other liver diseases. * Positive hepatitis B surface antigen. * Liver cirrhosis. * Uncontrolled psychiatric disease. * Clinical evidence of chronic cardiac disease. * History of malignancy of any organ system within 5 years.